Merozyne Therapeutics AB
Merozyne Therapeutics has been established to develop a pharmacological treatment for MDC1A.
MDC1A is a rare and severe form of muscular dystrophy caused by mutations in the gene encoding the protein laminin. MDC1A is a genetic disease and debuts in the first year of life and hinders the patients’ continued muscular development.
There is currently no cure for MDC1A. Patients have a degraded quality of life and often die before reaching adolescence.
The drug development program at Merozyne Therapeutics has the potential to offer new and unique possibilities to treat MDC1A. Such a new pharmaceutical treatment will provide improved quality of life and a prolonged life span for the patient.
MDC1A is an orphan-drug indication.
Press release 2016-11-14